May - June news updates from the EMA

22 June, 2017

In addition to the CVMP’s May and June meeting reports (Link), the EMA has published updates relating to the following topics:

  • New Q & A page on the “sunset clause” (Link)
  • News bulletin from the SME office (Link), summarising recent developments, including those concerning VMPs.
  • Documentation from the focus group on promotion of pharmacovigilance for food producing animals, 23Nov17 (Link)
  • Documentation from the focus group meeting on availability of Lumpy Skin Disease (LSD) vaccines authorised to EU standards, 31Jan17 (Link)
  • EMA monthly activity reports from April (Link) and May (Link)
  • Q & A on regulatory guidance for industry to prepare for the UK’s withdrawal from the EU (Link) and information about EMA planning (Link)
  • Updated explanatory note on general fees payable to the EMA (Link)
  • Focus group announced, with invited stakeholders on field efficacy trials in the context of an EU authorisation for veterinary vaccines, 22 – 23 June 2017 (Link).
  • Joint EMA/HMA Veterinary Vaccine Availability Action Plan - Analysis of industry recommendations (Link)
  • Availability of veterinary vaccines – webpage updated (Link)
  • Blue-box requirements update (Link)
  • Updated MUMS classification list (Link) and template for requesting MUMS classification (Link)

In addition there have been a number of eSubmission updates (Link):

  • Guideline on eSubmissions for Veterinary products – version 2.5 (tracked changes and clean versions published) and the eSubmission Validation checklist - version 2.5; entered into force June 2017
  • VNeeS Q&A relating to eSubmission for Veterinary Applications (updated May 2017)
  • Statement of intent on the stepwise implementation of VICH GL53
  • Version 1.21 of the eAFs (MAAs, variations and renewals) are now available (Link).


Business Units: 

Complete services for vaccines, immunologicals and biologicals

To learn more about our full range of support services for vaccines and other biological products, provided in collaboration with VVC, follow the link below.

Vaccines, biologicals and immunologicals